Related Experiment Video
Updated: May 15, 2026
10:44
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
Published on: February 22, 2015
Pain and multiple sclerosis: pathophysiology and treatment
Claudio Solaro1, Erika Trabucco, Michele Messmer Uccelli
1Head and Neck Department, Neurology Unit, ASL 3 Genovese, Largo Rosso 3, 16153, Genoa, Italy. csolaro@libero.it
Current Neurology and Neuroscience Reports
|December 20, 2012
Summary
Multiple sclerosis (MS) pain affects up to 75% of patients, impacting quality of life. Current pain management offers low patient satisfaction, highlighting the need for better research and treatment strategies.
Area of Science:
- Neurology
- Pain Medicine
- Multiple Sclerosis Research
Background:
- Pain is a prevalent and debilitating symptom in multiple sclerosis (MS), affecting up to 75% of patients.
- MS-related pain can arise from various causes, including direct disease effects and secondary symptoms like spasticity and fatigue.
- Pain management in MS is associated with low patient satisfaction, despite accounting for a significant portion of medication use.
Purpose of the Study:
- To review current data on pain in multiple sclerosis.
- To identify unmet needs and areas requiring further research in MS pain management.
- To emphasize the necessity of placebo-controlled trials for establishing treatment efficacy.
Main Methods:
- Literature review of existing studies on pain in multiple sclerosis.
- Analysis of reported prevalence, causes, and impact of pain in MS patients.
- Discussion of the limitations of current research methodologies, including open-label studies.
Main Results:
- Pain is a frequent and complex symptom in MS, significantly affecting patients' quality of life.
- Existing treatments show low patient satisfaction, indicating a gap in effective pain management.
- The majority of MS pain research relies on small, open-label studies, limiting generalizability.
Conclusions:
- Effective pain management strategies for multiple sclerosis patients are lacking.
- Further research, including ethical placebo-controlled trials, is crucial for validating new pain therapies.
- Addressing MS-related pain is essential for improving patient outcomes and quality of life.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:25Secondary Spinal Cord Injury llI: Pathophysiology
Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...